Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors.
about
Population Pharmacokinetic Meta-Analysis of Ramucirumab in Cancer Patients.Association of time-varying clearance of nivolumab with disease dynamics and its implications on exposure response analysis.Commentary on Pharmacometrics for Immunotherapy.Exposure-Response Analysis of Nivolumab in Patients With Previously Treated or Untreated Advanced Melanoma.Population Pharmacokinetics of Durvalumab in Cancer Patients and Association with Longitudinal Biomarkers of Disease Status.Nivolumab in recurrent/metastatic head and neck cancers.The role of nivolumab in melanoma.Clinical Pharmacology Considerations for the Development of Immune Checkpoint Inhibitors.Dose Rationalization of Pembrolizumab and Nivolumab Using Pharmacokinetic Modeling and Simulation and Cost Analysis.Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response.Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors.Immunotherapy in the Asiatic population: any differences from Caucasian population?Efficacy of Nivolumab in a Patient with Metastatic Renal Cell Carcinoma and End-Stage Renal Disease on Dialysis: Case Report and Literature Review.Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 TrialPharmacometric Applications and Challenges in the Development of Therapeutic Antibodies in Immuno-Oncology
P2860
Q38612237-A172408D-65E1-4723-AC51-D0383BCCC9B6Q38969901-34BC5B13-341E-4764-AEB8-FB6AFBCFD013Q39082975-82F3C8A1-B788-4918-AC1A-9D6C091AA3CBQ45367967-589D736D-5647-4BAB-BBA1-63D6A790F0F4Q47291273-2E0D5A14-32CF-48AD-BC1C-B654927E1562Q47610092-17B152F2-4AA0-467B-B120-675CF02BC539Q47735641-E89ADDAD-1667-4E65-821B-E5B8A898D619Q47943881-2D312D9E-97B5-48A2-9A14-A5B00E483FB4Q50074715-136D8890-7258-48DA-B841-36CCB313A24BQ50606627-F96D8F20-714C-46FC-8218-B5DFB1C55CD1Q50638216-11518386-3C10-4D52-886F-BD41A25A79DAQ55312983-8964CB93-5A09-4733-A0E0-7C451BEBBD5AQ55669081-66C3256D-37CA-4257-A072-1E2645AB38ADQ56383260-D7A02EDE-4814-4954-9C3F-CD7C1C4FA585Q57495826-56262C0C-32A9-45F0-BF90-98475B3F7B29
P2860
Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 December 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Model-Based Population Pharmac ...... in Patients With Solid Tumors.
@en
Model-Based Population Pharmac ...... in Patients With Solid Tumors.
@nl
type
label
Model-Based Population Pharmac ...... in Patients With Solid Tumors.
@en
Model-Based Population Pharmac ...... in Patients With Solid Tumors.
@nl
prefLabel
Model-Based Population Pharmac ...... in Patients With Solid Tumors.
@en
Model-Based Population Pharmac ...... in Patients With Solid Tumors.
@nl
P2093
P2860
P356
P1476
Model-Based Population Pharmac ...... in Patients With Solid Tumors.
@en
P2093
P2860
P356
10.1002/PSP4.12143
P577
2016-12-26T00:00:00Z